EZH2 and prostate carcinoma: Specifically, prostate cancer organoids cultured in Arg-Glu-Asp-Val (REDV)-functionalized hydrogels showed reduced actin symmetry under enhancer of zeste homolog 2 (EZH2) inhibition, illustrating ECM-dependent drug responses [458].